Ocugen, Inc.: directors' dealings · United States · SEC (Form 4)

About Ocugen, Inc.

Ocugen, Inc. is a U.S.-listed biotechnology company trading on the NASDAQ exchange in the United States. Headquartered in Malvern, Pennsylvania, the company was co-founded in 2013 and has built its profile around gene and cell therapy programs, with a strong emphasis on ophthalmology and rare retinal diseases. Unlike a diversified large-cap pharma company, Ocugen is a development-stage biotech whose valuation is driven primarily by clinical progress, regulatory milestones, and partnering opportunities rather than by established commercial sales. The company’s core franchise is centered on a pipeline of genetic medicines designed to address serious, underserved eye disorders. Its lead program, OCU400, is being advanced as a gene therapy candidate for retinitis pigmentosa, an inherited retinal disease that can lead to progressive vision loss. Ocugen is also developing OCU410ST for Leber congenital amaurosis and related retinal disorders, along with additional ocular programs such as OCU200. In practical terms, the business model is typical of a platform biotech: create differentiated assets, advance them through clinical development, and seek value creation through regulatory approvals, partnerships, and eventual commercialization or licensing. From a competitive standpoint, Ocugen operates in a crowded and capital-intensive field dominated by larger biotech peers, specialty ophthalmology companies, and gene-therapy developers with deeper balance sheets. Its strategic advantage lies in its focus on rare eye diseases, where unmet medical need remains high and even modest clinical differentiation can have outsized strategic value. The company also uses licensing and collaboration agreements to expand reach and reduce development risk, particularly in international markets. Recent developments indicate that Ocugen remains in a pre-revenue or early-revenue build-out phase, but with continued momentum across its pipeline. In 2026, the company released quarterly financial updates, discussed capital-raising activity, and highlighted that its cash position had been extended by financing and warrant exercises. Management has also been active in investor presentations and industry events, underscoring the importance of near-term catalysts. For investors, Ocugen should be viewed as a speculative ophthalmic biotech with meaningful upside tied to clinical execution, but also substantial binary risk typical of emerging gene-therapy developers.